Current use of dendritic cells in cancer immunotherapy

View/ Open
File version
Version of Record (VoR)
Author(s)
Lopez, JA
Hart, DNJ
Griffith University Author(s)
Year published
2002
Metadata
Show full item recordAbstract
Dendritic cells (DCs) initiate and direct the immune response. Their inability to detect danger signals from transformed cells and to generate an effective immunological response may allow cells with a malignant phenotype to evolve into cancers. This defect can be corrected for many cancer types and the immune response boosted to eliminate malignant cells by means of DC-based vaccines/therapies. Rapid advances in our understanding of basic DC physiology and improved methods for DC isolation have made clinical application of DC therapy practical and encouraging phase I/II results are emerging.Dendritic cells (DCs) initiate and direct the immune response. Their inability to detect danger signals from transformed cells and to generate an effective immunological response may allow cells with a malignant phenotype to evolve into cancers. This defect can be corrected for many cancer types and the immune response boosted to eliminate malignant cells by means of DC-based vaccines/therapies. Rapid advances in our understanding of basic DC physiology and improved methods for DC isolation have made clinical application of DC therapy practical and encouraging phase I/II results are emerging.
View less >
View less >
Volume
4
Issue
1
Publisher URI
Copyright Statement
© 2002 Pharma Press. After all reasonable attempts to contact the copyright owner, this work was published in good faith in interests of the digital preservation of academic scholarship. Please contact copyright@griffith.edu.au with any questions or concerns.
Subject
Biomedical and clinical sciences
Tumour immunology